Size | Price | |
---|---|---|
10mg | ||
10mg | ||
25mg | ||
50mg | ||
100mg | ||
250mg |
Purity: ≥98%
ln Vivo |
The number of spontaneously active A10 dopamine cells was significantly reduced in male rats that received acute doses of 0.1 (n=21) and 0.3 (n=5) mg/kg of zatosetron maleate (Zatosetron), but not of 0.01, 0.05, 1.0, or 10 mg/kg (n=5, 3, 6, and 4 respectively) of zaltosetron maleate or saline (n= 5). After receiving 0.1 mg/kg of zaltosetron maleate intraperitoneally, the number of spontaneously active A10 dopamine cells did not change significantly between 30 and 60 minutes, but it did significantly decrease between 60 and 90 minutes (0.65±0.11, P=0.03, n = 5), from 90 to 120 minutes (0.53±0.08, P=0.004, n = 5), and from 2 to 3 hours (0.50+0.05, P=0.0004, n = 5). After intravenous injection, zaltosetron maleate (ED50=0.12 mg/kg, n=8) inhibited the activity of A10 dopamine cells, according to single-unit recordings. Chronic zaltosetron maleate administration of 0.1 mg/kg (n = 16) was found to significantly reduce the number of spontaneously active A10 dopamine cells, but not that of 0.01, 1.0, or 10 mg/kg (4, 8, and 7 respectively) or saline (n = 5).
|
---|---|
References |
[1]. Robertson DW, et al. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
[2]. Rasmussen K, et al. The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol. 1991 Nov 19; 205 (1):113-6 |
Molecular Formula |
C19H25N2O2CL.C4H4O4
|
---|---|
Molecular Weight |
464.93916
|
CAS # |
123482-23-5
|
Related CAS # |
123482-22-4 (Zatosetron)
|
SMILES |
O=C(C1=C(OC(C)(C)C2)C2=CC(Cl)=C1)NC3CC(N4C)CCC4C3.O=C(O)/C=C\C(O)=O
|
InChi Key |
HAFQATMFFHYNPN-BTJKTKAUSA-N
|
InChi Code |
InChI=1S/C19H25ClN2O2.C4H4O4/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3;5-3(6)1-2-4(7)8/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
|
Chemical Name |
7-Benzofurancarboxamide, 2,3-dihydro-5-chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-, (Z)-2-butenedioate (1:1)
|
Synonyms |
Zatosetron maleate
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1508 mL | 10.7541 mL | 21.5082 mL | |
5 mM | 0.4302 mL | 2.1508 mL | 4.3016 mL | |
10 mM | 0.2151 mL | 1.0754 mL | 2.1508 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.